Upcoming event

Tags

Abiraterone, abiraterone acetate, ACP3 PET, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, apalutamide, ARCHES, Article of the Month, artificial intelligence, ASCO GU21, ASCO GU22, ASCO2026, ASCO21, ASCO26, AUA21, BHC80, Biochemical recurrence, biomarker, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, CAPItello-281, capivasertib, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, darolutamide, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, high-risk prostate cancer, homologous recombination repair, hormone-sensitive, HORRAD, HRQL, HRR-deficient mCSPC, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, locally advanced prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, mCSPC, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, metastatic castration-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, PEACE-1 trial, pelvic lymph node dissection, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, prednisone, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, PRIMARY2, Prognosis, Prognostic model, Prostasomes, prostate cancer, prostate cancer screening, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PROTEUS study, PSA, PSA flare, PSA kinetics, PSA screening, PSMA, PSMA PET/CT, PTEN, PTEN deficiency, Quality of life, Radiation therapy, Radical prostatectomy, radioligand therapy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Summer read, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, TALAPRO-3 study, talazoparib, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, UROonco25, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Influence of Sociodemographic Factors on Definitive Intervention Among Very Low- and Low-Risk Active Surveillance Patients

Journal of Urology, September 2021

Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study

Cancer, August 2021

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study

European Urology, August 2021

A comparison of 18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer

The Journal of Nuclear Medicine, September 2021

Diagnostic Performance of 68 Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer

Radiology, August 2021

Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities

Journal of Urology, August 2021

Why does MRI-targeted biopsy miss clinically significant cancer?

Journal of Urology, August 2021

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial

Lancet Oncology, August 2021

Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups

European Urology, August 2021

Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting

European Urology Focus, August 2021

A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients

Journal of Nuclear Medicine, July 2021

Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer

BJU International, August 2021

PreviousNext